(CIDRAP News) – US influenza policy experts who gathered in Washington, DC, today called for better vaccines and other steps for improving pandemic and seasonal flu preparedness, themes echoed in an action plan released by the Infectious Diseases Society of America (IDSA).
(CIDRAP News) Speaking at a Senate committee hearing today, US Health and Human Services (HHS) Secretary Kathleen Sebelius said a cell-based seasonal influenza vaccine from Novartis could be on the US market in time for the 2011-12 flu season.
(CIDRAP News) Commonly available drugs that are sold in lower-cost generic versions improve the survival of patients hospitalized for seasonal influenza, researchers reported today, raising the possibility of a widely available treatment that could be used in a severe flu pandemic if other drugs are in short supply.
(CIDRAP News) Requests to use the intravenous (IV) antiviral drug peramivir in hospitalized H1N1 flu patients came quickly after the government issued an emergency use authorization (EUA) Oct 23, a Centers for Disease Control and Prevention (CDC) official said today.
(CIDRAP News) – At an Infectious Diseases Society of America (IDSA) symposium in Washington, DC, today on seasonal and pandemic influenza, a group of experts fielded questions from reporters on some of the new trends and emerging issues, including prepandemic strategies for H5N1 avian influenza vaccines, now that some countries are stockpiling them.
(CIDRAP News) This in-depth article investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. Its seven parts put advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.
Editor's note: This is the bibliography to a seven-part series launched October 25, 2007, investigating the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. The series puts advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.